Friday, May 29, 2015 Last update: 3:03 AM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Biomedical / Biotech / Health News

Thursday, May 28, 2015

  • Posted at 5:00 AM
    MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company, announced today that its President and Chief Executive Officer, David Hansen, will present at the LD Micro Invitational Investor Conference being held at the Luxe Sunset Hotel in Bel Air, California on June 1-3, 2015. Mr. Hansen will present a corporate update including highlights from the significant progress made in the last year and plans for continuing development of its lead antibody candidate HuMab 5B1 as a diagnostic ... read more
  • Posted at 5:00 AM
    Human resource software vendors increasingly are developing new products as native applications for smartphones before moving them to laptops and personal computers, providing immediate and 24/7 access to a wide range of HR, talent and learning applications, according to new research from Bersin by Deloitte. Summarized in a WhatWorks® Brief, the research findings appear in "Smartphone Support in Talent and HR Applications 2015." (Bersin by Deloitte will publish a companion study on user preferences in June). http://photos.prnewswire.com/prnvar/20130122/NY45906LOGO The study found that 93 ... read more
  • Posted at 5:00 AM
    Momentum, launching at BookExpo America 2015, provides a new way to generate organic, word-of-mouth marketing by utilizing "social unlocks", an approach to encouraging engagement on social media that rewards fans as a community for their support by unlocking exclusive content. Until now, this form of social marketing has been complicated to launch and the software necessary to run campaigns has been expensive to build and often restricted to a single social network. Momentum, a hosted, subscription-based software platform, makes social ... read more
  • Posted at 5:00 AM
    Cypher Genomics, Inc., the leading genome informatics company, and the Clinic for Special Children today announced a collaboration in which Cypher's automated genomic interpretation tools will be utilized for the diagnosis of rare genetic diseases among a unique population. Located in Strasburg, Pennsylvania, the Clinic for Special Children (CSC) serves many Amish and Mennonite patients, a founder population with a relatively high incidence of genetic disease. "We are very excited to partner with such a distinctive and highly regarded organization," ... read more
  • Posted at 5:00 AM
    Strategy Analytics (www.strategyanalytics.com) has identified that the camera of a smartphone is the most-used, on-device feature thus far, while also being a consumers' number one priority when purchasing a new mobile device. It is clear that users are always looking for value-added features to improve their photo capturing experience. http://photos.prnewswire.com/prnvar/20130207/NE56457LOGO-b A recent study from the Wireless Device Lab (WDL) at Strategy Analytics, surveying smartphone camera behaviours, found that when capturing a photo, consumers are most interested in 'lining up the ... read more
  • Posted at 5:00 AM
    Eli Lilly and Company (NYSE: LLY) announced that data from several trials of CYRAMZA(®) (ramucirumab) will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, including a Phase II study of non-small cell lung cancer (NSCLC) patients in Japan. Other data, including those from global Phase III studies of CYRAMZA in gastric, non-small cell lung, and hepatocellular cancers, will also be presented at the meeting. "In just over a year, CYRAMZA received four full FDA approvals ... read more
  • Posted at 5:00 AM
    Prometheus Laboratories, Inc. announced today the presentation of data from patients enrolled in the PROCLAIM(SM) national patient registry, demonstrating the safety and efficacy of Proleukin(®) (aldesleukin for injection) when treated in sequence with checkpoint therapy in patients with metastatic melanoma (mM). In a poster session to be presented on May 30(th) at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, investigators describe favorable safety results for Proleukin when administered after therapy directed against the ... read more
  • Posted at 5:00 AM
    Eli Lilly and Company (NYSE: LLY) announced today that pursuant to its previously announced cash tender offer for up to $1.6 billion aggregate principal amount (the "tender cap") of specified series of its outstanding debt, approximately $1.45 billion in aggregate principal amount of the notes listed in the table below were validly tendered and not validly withdrawn on or prior to 5:00 p.m., New York City time, on May 27, 2015, the early tender date for the offer. The table ... read more
  • Posted at 5:00 AM
    Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM(SM) national patient registry in which first-line Proleukin(®) (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies. In a presentation at the 51st annual meeting of the American Society of Clinical Oncology (ASCO), researchers presented updated survival data from the PROCLAIM mRCC retrospective cohort, along with new data from the mRCC prospective cohort, that confirm ... read more
  • Posted at 5:00 AM
    Good Technology(TM), the leader in secure mobility, today announced that North Hennepin Community College is using Good Enterprise Suite to provide its BYOD solution, enabling secure access to work emails, student assignments, strategic plans, and more and setting the stage for a new era in higher learning at the school. http://photos.prnewswire.com/prnvar/20120125/AQ41496LOGO-b North Hennepin Community College, part of the Minnesota State Colleges and Universities system, is one of the largest community colleges in the state with over 10,000 students and 500 employees. ... read more
  • Posted at 5:00 AM
    Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, today appointed Patrick Hall, D.Ph., to the newly created role of Executive Director, Medical Affairs and announced the promotion of Robert W. Cook, Ph.D. The Company also announced the expansion of its sales force ... read more
  • Posted at 5:00 AM
    Pfizer announced initial results of its global survey of more than 3,600 adults with rheumatoid arthritis (RA) in 13 countries. The RA NarRAtive patient survey is the first of its kind to simultaneously evaluate the patient and healthcare professional (HCP) relationship and communication, as well as ... read more
  • Posted at 5:00 AM
    Raze Therapeutics, a leading next-generation cancer metabolism company, announced today the addition of Robert Copeland, PhD, President of Research and Chief Scientific Officer at Epizyme, Inc., to its Scientific Advisory Board (SAB). Dr. Copeland brings deep experience in oncology drug ... read more
  • Posted at 5:00 AM
    TORONTO, ON--(Marketwired - May 28, 2015) - Following the immense success of two previous gatherings in Toronto, the International Society for Magnetic Resonance in Medicine (ISMRM) is returning to the city for a third time. This year's 23rd Annual Meeting will see approximately 5,700 clinicians, physicists, engineers, biochemists, and technologists from around the world at the Metro Toronto Convention Centre (MTCC), injecting the local economy with an estimated $16 million in economic impact."We were ... read more
  • Posted at 5:00 AM
    SEATTLE, WA -- (Marketwired) -- 05/28/15 -- Atossa Genetics Inc. (NASDAQ: ATOS) announced today that it has entered into a $25 million stock purchase agreement with Aspire Capital Fund, LLC. Under terms of the agreement, after the SEC declares the registration statement related to the transaction effective, Aspire has committed to purchase up to $25 million of Atossa's common stock over 30 months based on prevailing market prices over a period preceding each sale. "By securing this important financing agreement, ... read more
  • Posted at 4:30 AM
    Pronutria Biosciences, a clinical stage biotechnology company pioneering a new class of therapeutics to mediate amino acid biology, today announced the successful completion of a $39 million Series C financing led by new investor Fidelity Management & Research Company and joined by founding investor Flagship Ventures, ... read more
  • Posted at 4:30 AM
    Labcyte Inc., a company revolutionizing life science research with its patented acoustic liquid handling technology, today announced expanded capabilities for the Echo® 525 liquid handler with the introduction of the Echo qualified reservoir, a liquid handler source plate designed to enable convenient assay assembly and efficient ... read more
  • Rigel to Present at Jefferies 2015 Global Healthcare Conference --- SOUTH SAN FRANCISCO, Calif., May 28, 2015
    Posted at 4:30 AM
    Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies 2015 Global Healthcare Conference in New York City on Wednesday, June 3rd at 1:30 p.m. ET. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download ... read more
  • Posted at 4:30 AM
    Biscayne Pharmaceuticals, Inc., today announced that data supporting the anti-cancer potential of its growth hormone-releasing hormone (GHRH) technology will be discussed in a poster presentation at the 2015 ASCO Annual Meeting. The data show that the family of receptors for GHRH, the target for Biscayne's anti-cancer GHRH blockers, is present on many primary breast cancer cells regardless of hormone receptor status. These findings suggest that GHRH antagonists could have broad anti-cancer potential in breast cancer.(1) GHRH is primarily made in the ... read more
  • Posted at 4:30 AM
    Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation, cocaine use disorder and other addictions, today announced the first subject received the initial dose in a Phase 1 clinical trial evaluating EMB-001. A novel combination of ... read more